Lenabasum Fails to Lessen Exacerbations in CF Patients in Phase 2 TrialOct 07, 2020 07:30 am | Marisa Wexler MS
A Phase 2 clinical trial of oral lenabasum in people with cystic fibrosis (CF) failed to meet its primary goal of reducing pulmonary exacerbations, the investigational therapy’s developer, Corbus Pharmaceuticals, announced. “We are very disappointed that the study did not meet the primary endpoint,” Barbara White, MD, chief medical officer and head of research at Corbus, said in a company press […]
The post Lenabasum Fails to Lessen Exacerbations in CF Patients in Phase 2 Trial appeared first on Cystic Fibrosis News Today. |
|
Same But Different Asks Public to Vote on ‘Glimmer of Hope’ Calendar PhotosOct 07, 2020 07:30 am | Mary Chapman
Same But Different, a nonprofit U.K. group that uses art for social change, is inviting people to choose their favorite photographs in a calendar contest to heighten awareness of rare diseases, including amyotrophic lateral sclerosis (ALS). The organization’s panel of judges has pared the number of contest submissions to 24, for the voting public to select […]
The post Same But Different Asks Public to Vote on ‘Glimmer of Hope’ Calendar Photos appeared first on Cystic Fibrosis News Today. |
|
Twincer Inhaler May Be Better Alternative to Nebulizers for Colistin TreatmentOct 06, 2020 07:00 am | Teresa Carvalho
Twincer, a dry powder inhaler (DPI), was shown to be a more attractive approach for the inhalation of colistin — an antibiotic used to treat lung infections in people with cystic fibrosis (CF) — when compared with a nebulizer, according to a new study. The findings were reported in “Colistin dry powder inhalation with the Twincer™: […]
The post Twincer Inhaler May Be Better Alternative to Nebulizers for Colistin Treatment appeared first on Cystic Fibrosis News Today. |
|
|
No hay comentarios:
Publicar un comentario